BURBANK, Calif., April 30, 2018 (GLOBE NEWSWIRE) -- Imaging3, Inc. (OTCQB:IGNG), a development stage
company introducing disruptive technologies in the medical imaging industry, announced today the appointment of George Zdasiuk,
PhD, to its Board of Directors. In addition, Dr. Zdasiuk will also serve as the Chairman of the Company’s recently announced
Scientific Advisory Board.
Dr. Zdasiuk will assist Imaging3 on all matters pertaining to product development, regulatory and commercial
strategy, with the goal of maximizing the global market impact and value realization from the Company’s highly disruptive Dominion
SmartScan™ technology. From 1980-2015, Dr. Zdasiuk was employed by Varian Medical Systems (formerly, Varian Associates), a
leader in the fields of radiotherapy, radiosurgery, X-ray tube technology and digital imaging, in roles including Chief Technology
Officer and Senior VP/ Director of Varian’s Ginzton Technology Center. Varian employs 6,500 people across the globe and is
recognized as a pioneer in the field of radiotherapy and medical imaging. Dr. Zdasiuk was responsible for investigating new
disruptive technologies, conducting feasibility studies and incubating start-up businesses within Varian. Dr. Zdasiuk earned
a Ph.D. in Applied Physics from Stanford University, specializing in photonics systems and non-linear optics. Dr. Zdasiuk
received his BASc, with highest honors, in Engineering Science and his MS in Physics from the University of Toronto.
“We are very excited to have Dr. Zdasiuk joining our Board of Directors,” noted John Hollister, CEO of
Imaging3. “George’s track record speaks for itself, in both the professional and academic arenas, and his leadership on
our Scientific Advisory Board will be invaluable. We look forward to drawing upon his extensive industry experience as we
develop our technology and progress towards commercialization.”
“The Imaging3 Dominion SmartScan technology appears to offer some important and novel combinations of value
propositions that I expect will position them with the ability to address previously under-served or un-served segments of the
global market. This potential for many novel use areas presents a fascinating development challenge and commercial
opportunity, and I look forward to helping the Imaging3 team achieve their goals,” said Dr. Zdasiuk.
Jeffrey N. Peterson, Chairman of Imaging3, said “Our efforts in re-building and leading the Company to achieve its
global market potential require that we complete the assembly of a world-class management team and Board of Directors. Dr.
Zdasiuk is a globally-recognized scientific leader in the medical imaging industry, with diverse experience in nurturing and
commercializing innovative new technologies, and we are honored and pleased to welcome him to the Imaging3 Board.”
About Imaging3, Inc.
Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called the Dominion SmartScan™,
that produces 3D x-ray images, effectively in real time. The SmartScan technology has the potential to allow healthcare
professionals to perform diagnostic and therapeutic procedures more quickly and accurately, which may result in higher throughput
for the clinicians and fewer safety risks for patients. Imaging3’s technology exposes patients to less harmful
radiation than current equivalent imaging technologies such as CT scans. The company believes this will allow scans to be
used in many settings where scanning is currently limited by concerns about radiation exposure. The technology also notably allows
for reasonably convenient portability, easier installation and use-readiness, and a significantly reduced cost burden suitable for
novel settings and for healthcare systems across varied global settings. Imaging3 plans to submit a 510(k)
application to FDA during 2018 to gain marketing authorization for initial applications for the SmartScan technology.
Visit the company’s website at http://www.imaging3.com for detailed information about the company’s technology.
Safe Harbor for Forward-Looking Statements
Imaging3 cautions you that any statement included in this press release that is not a description of historical facts
is a forward-looking statement. Many of these forward-looking statements contain the words "anticipate," "believe," "estimate,"
"may" "intend," "expect" and similar expressions. Actual results, performance or achievements could differ materially from those
contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based
largely on the expectations of the company and are subject to a number of risks and uncertainties inherent in Imaging3’s
business, including, without limitation: the company may not ever obtain FDA clearance or approval for any of its devices; the
company may not be able to secure the funds necessary to support its product development plans; and the company may not ever
achieve the market success to sustain a profitable business. In addition, there are risks and uncertainties related to
economic recession or terrorist actions, competition from much larger imaging companies, technological obsolescence, unexpected
costs and delays, potential product liability claims, and many other factors. More detailed information about Imaging3
and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the
Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q.
Such documents may be read free of charge on the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their
entirety by this cautionary statement, and Imaging3 undertakes no obligation to revise or update this press release to
reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E
of the Private Securities Litigation Reform Act of 1995.
Investor Relations:
Mike Cole
Vice President
MZ Group - MZ North America
+1(949) 259-4988
mike.cole@mzgroup.us
www.mzgroup.us
